6 Best Peptides for Keloids

What to Know Before Choosing a Peptide for Keloids

Keloids are one of the more stubborn problems in skin biology. They form when the wound-healing process loses its off switch, producing a raised, firm scar that extends beyond the original injury site and does not shrink on its own. The molecular driver is an overactive signaling protein called TGF-beta1, which instructs fibroblasts to keep manufacturing collagen long after the wound is closed. Conventional first-line treatments like corticosteroid injections and silicone sheeting work reasonably well for many people, but recurrence is common, and for those whose keloids resist standard care, the search for additional options is real.

That search has led a growing number of people to peptides. A compound earns a place in this guide for one reason: people are using it or actively discussing using it for keloids. The entries here span every tier of availability, from widely sold topical skincare ingredients to laboratory-stage research chemicals to a peptide that has completed a Phase II clinical trial for scar improvement. FDA approval status and evidence depth are never the filter for inclusion. They govern how each compound is described, not whether it appears. A compound whose evidence comes entirely from cell cultures belongs here, and its entry says exactly that rather than glossing over it.

The numbers in front of the entries are a spine for the list, not a verdict. The order reflects how prominently each compound appears in the research literature and in real-world use for keloids, not a recommendation of one compound over another. The right choice for any individual depends on factors this article cannot see, which is exactly why the MyPeptidePal app exists. This guide maps the field. The app builds the plan.

One honest framing before the entries begin: no peptide has been evaluated in a completed human clinical trial specifically for keloids as of 2026. Several carry strong preclinical data. One has Phase II scar trial data that does not focus on keloids specifically. A few rest mostly on community-reported use. That full spectrum is represented, with the evidence for each stated plainly.

1. GHK-Cu: The Most Accessible Starting Point

GHK-Cu is a copper tripeptide that occurs naturally in human plasma, composed of glycine, histidine, and lysine bound to a copper ion. It is the peptide people most consistently reach for in skin-health communities when the topic turns to scars and keloids, and the reasons are practical: it is widely available as a topical ingredient, it has a long research history in skin biology more broadly, and its safety profile is extremely well established.

The way GHK-Cu works for keloids is worth understanding precisely, because it differs from the more targeted antifibrotic compounds later in this list. Rather than directly blocking the TGF-beta signaling pathway that drives keloid fibrosis, GHK-Cu influences collagen remodeling more generally. It supports the repair and reorganization of existing collagen architecture, reduces skin inflammation, and encourages more organized tissue regrowth rather than the disordered overproduction that produces keloid tissue. Think of it less as a brake on the keloid process and more as a normalizing signal for connective tissue behavior.

No published clinical trial has evaluated GHK-Cu specifically for keloids as of 2026. What exists is a well-established body of research on its role in skin repair and collagen metabolism, combined with a meaningful volume of community-reported use. User reports are genuinely mixed. Some people cycling GHK-Cu over multiple months describe meaningful flattening of raised scars and a lightening in pigmentation; one frequently cited account from the r/Peptides community describes a stomach keloid becoming completely flat after sustained use across multiple cycles. Others report no noticeable change after six weeks. The pattern that has emerged points toward patience: meaningful results, when they occur, tend to arrive over three to six months rather than weeks, and the effect appears more consistent for scar texture and height reduction than for complete keloid elimination.

GHK-Cu was removed from the FDA's "do not compound" list in April 2026, though it is not yet formally approved for compounded human therapeutic use. It is broadly available as a topical cosmetic ingredient and as a research-grade powder from peptide retailers. The topical form has no identified contraindications even in sensitive populations, with rare and mild skin redness representing the outer edge of reported reactions.

For someone beginning to explore peptides for keloids, GHK-Cu is usually the first conversation for a reason. It is the most accessible, the most studied in general skin biology, and its safety ceiling is clear. It is not the most mechanistically targeted option for active keloid fibrosis, but it is a legitimate entry point with real-world use behind it.

2. LL-37: The Compound Most Directly Tied to Keloid Biology

LL-37 is the only cathelicidin the human body produces, an endogenous antimicrobial peptide made by immune cells and epithelial tissue. It earned its position near the top of keloid-specific research for a striking biological reason: in human dermal keloid tissue, the severity of fibrosis is inversely related to LL-37 expression. The lower the LL-37 level in the tissue, the worse the keloid. That inverse relationship is not just statistically interesting; it points directly at LL-37 as a natural biological regulator of the very process that makes keloids what they are.

Mechanically, LL-37 inhibits TGF-beta-induced collagen expression through a pathway involving a G protein-coupled receptor and a signaling cascade that blocks the phosphorylation of Smad2 and Smad3. These proteins act as messengers that carry the TGF-beta signal into the cell nucleus and instruct the DNA to keep producing collagen. When LL-37 interferes with their activation, that instruction is quieted. Research has confirmed this effect at nanomolar concentrations in human keloid cell cultures, meaning the compound is biologically active at very low levels in the relevant tissue type.

The evidence base is in vitro work using actual human dermal keloid cells, which is a stronger experimental model than generic cell cultures or rodent tissue. No human clinical trial has been initiated for LL-37 in keloids as of 2026. The translation from cell cultures to a usable human therapy involves real challenges around delivery, stability, and safety that the research community is still working through. LL-37 is available through research-chemical channels but has no established human use protocol and is not accessible through any regulated clinical pathway for this application.

For readers tracking the science, LL-37 is arguably the most biologically compelling compound on this list for keloid-specific fibrosis. For readers looking for something they can use today, it is a research-stage option rather than a practical one.

3. ADP355: For Directly Blocking the Fibrosis Cascade

ADP355 is a synthetic peptide designed to mimic adiponectin, a hormone produced by fat tissue with well-characterized anti-inflammatory and antifibrotic properties. The engineered peptide engages adiponectin receptors with greater stability than the natural hormone, making it a more viable research compound for sustained study.

The mechanism is specific and well-mapped for keloids. ADP355 activates a signaling protein called AMPK, which functions as a cellular energy sensor and directly suppresses TGF-beta1-induced procollagen expression. Activating AMPK is one of the cleaner ways to turn down the collagen overproduction signal in keloid fibroblasts. Simultaneously, ADP355 inhibits Smad3 phosphorylation, cutting off the TGF-beta signal at a key relay point, and it downregulates ERK, a pro-fibrotic proliferation pathway. In xenograft mouse models, where researchers implanted actual human keloid tissue and measured the response to treatment, the compound produced a significant reduction in total keloid tissue weight and a measurable decrease in procollagen expression.

The xenograft model is worth highlighting. Implanting human keloid tissue into mice and treating with ADP355 is a more direct experimental approach for keloid behavior than generic fibrosis assays. The results were strong enough that researchers identified ADP355 as a therapeutic candidate and called for further pharmacokinetic work and Phase I safety trials before human use could proceed.

No human trial has begun. ADP355 is a research-chemical compound, available from peptide retailers for laboratory use, with no established human dosing protocol or regulated clinical pathway. Its evidence base is preclinical, but it is among the most targeted and mechanistically specific options identified for keloid fibrosis as of 2026.

4. AlphaCT1: The Most Clinically Advanced Option

AlphaCT1 occupies a different position from every other compound on this list because it has been through a Phase II randomized controlled trial. The trial studied scar improvement broadly rather than keloids specifically, but a 47% improvement in scar appearance at nine months is a clinical finding that no other peptide discussed here can match.

The compound works by modulating connexin 43, a gap junction protein involved in cell-to-cell communication at wound sites. Gap junctions are channels that allow neighboring cells to share signals rapidly during tissue repair. Connexin 43 activity during the inflammatory and proliferative phases of wound healing influences how much scar tissue forms and how organized it is. AlphaCT1 adjusts that signaling at a structural level, encouraging scar formation that is flatter, better pigmented, and less excessive.

The honest qualification is that the Phase II data covers scars in general rather than keloids specifically. Keloids involve a more aggressive fibrotic process than typical hypertrophic scars, and whether the Phase II scar findings translate directly to keloid tissue has not been confirmed. AlphaCT1 is not FDA-approved for keloids or any scar indication as of 2026, and it is not available through any regulated clinical pathway outside of trial contexts. It is discussed in research-oriented communities and scar biology literature as one of the more promising candidates precisely because the Phase II data exists.

For readers tracking clinical progress, AlphaCT1 is the compound closest to the clinical threshold. For readers expecting an available treatment, the gap between Phase II trial evidence and an accessible, approved product remains real.

5. FOXO4-DRI: For the Senescent Cell Dimension

FOXO4-DRI takes a fundamentally different approach from every other compound on this list. Where the others target collagen production or TGF-beta signaling directly, FOXO4-DRI targets senescent cells, specifically the aging, dysfunctional fibroblasts that accumulate in keloid tissue and secrete a sustained cocktail of pro-inflammatory signals known as the senescence-associated secretory phenotype, or SASP. Those signals do not produce collagen directly, but they maintain the inflammatory environment that keeps the fibrosis process running.

The peptide is engineered using D-amino acids in a retro-inverso configuration, which makes it resistant to enzymatic breakdown in tissue. It disrupts the interaction between a protein called FOXO4 and p53, a key cellular stress regulator. In healthy cells, this interaction helps protect cells from apoptosis, which is programmed cell death. In senescent cells, FOXO4 traps p53 in a way that keeps the dysfunctional cell alive and secreting SASP signals rather than clearing itself. FOXO4-DRI breaks that interaction, freeing p53 to trigger apoptosis in the senescent cell while leaving healthy surrounding cells intact.

In ex vivo experiments using actual human keloid tissue, the effect was substantial. Collagen production fell by roughly 70%, tissue thickness decreased by approximately 35%, and apoptotic activity in the tissue increased nearly threefold compared to untreated samples. The authors of the study explicitly called for progression to Phase I clinical trials, a signal that the research community considers the preclinical evidence compelling enough to warrant human testing. No such trial has been initiated as of 2026.

FOXO4-DRI is discussed in biohacking and longevity communities primarily as a senolytic, a class of compounds designed to selectively clear senescent cells. Its keloid application sits at the intersection of that senolytic literature and the keloid biology literature. It is a research-stage compound with no human use protocol, available from research-chemical retailers. The ex vivo data is genuinely striking, and the mechanism addresses a dimension of keloid pathology that the other compounds here do not touch.

6. BPC-157: Used for Wounds but Carries a Keloid-Specific Caution

BPC-157 is one of the most broadly discussed peptides in tissue repair contexts. Derived from a protein found in gastric juice, it is a synthetic 15-amino-acid compound with well-characterized effects on angiogenesis, the growth of new blood vessels, and organized collagen synthesis during the acute phase of wound healing. For injuries like tendon tears, muscle damage, and gut inflammation, it has a substantial preclinical track record across a wide range of tissue types.

The keloid context is more complicated, and that complication deserves a direct explanation. The same angiogenic activity that makes BPC-157 useful for tissue repair raises a mechanistic concern for people who form keloids. Keloid formation is associated with elevated vascular density and disordered blood vessel growth in scar tissue. Promoting angiogenesis in someone with a genetic predisposition to keloids theoretically risks amplifying that disordered growth rather than correcting it. This concern is active in peptide communities, with dedicated discussions asking specifically whether BPC-157 increases keloid or hypertrophic scarring risk in susceptible individuals.

No published research has confirmed that BPC-157 worsens keloids. The concern is theoretical and mechanistically grounded rather than demonstrated in a controlled study. There is equally no published research evaluating BPC-157 in keloid tissue to provide reassurance in either direction. The compound simply has not been studied for this application.

BPC-157 is not FDA-approved for human therapeutic use and is available from research-chemical retailers. The community picture for this compound in the keloid context is one of caution rather than enthusiasm. People without a history of keloid formation use it freely for wound healing, while those who are keloid-prone tend to approach it carefully or avoid it for scar management purposes. It is included here because the question is actively discussed and the honest answer belongs in a complete guide rather than left for readers to search for separately.

How These Peptides Compare

Frequently Asked Questions

Are any peptides FDA-approved specifically for keloids?

No peptide is FDA-approved specifically for keloid treatment as of 2026. The FDA has approved peptide drugs for other conditions, including diabetes and growth hormone disorders, but the keloid-specific peptide field remains entirely preclinical or in early clinical stages. AlphaCT1 is the closest exception, with Phase II trial data for general scar improvement, but that approval pathway is incomplete and the data does not focus on keloids specifically.

How do peptides compare to corticosteroid injections for keloids?

Corticosteroid injections, particularly triamcinolone, remain the most reliably effective first-line treatment for keloids and carry decades of clinical use behind them. Community accounts consistently describe significant flattening within weeks of starting injections. Peptides work more slowly, have a thinner evidence base for keloids specifically, and serve better as complementary options or investigational alternatives for people who have not responded to standard care. They are not a replacement for proven medical treatments.

Is GHK-Cu safe to use on active keloid tissue?

The topical form of GHK-Cu has a well-established safety profile in skin applications, with no serious adverse reactions identified in cosmetic research and no contraindications for most populations. Applying it to keloid tissue does not carry the same theoretical concern as BPC-157's angiogenic activity. That said, no clinical safety data exists specifically for GHK-Cu applied to active keloid tissue, so the safety picture is based on general topical peptide use rather than keloid-specific study.

Why is the clinical evidence so thin for a condition this common?

Keloids are genuinely difficult to study with peptides. Clinical trial design requires consistent patient populations, long follow-up periods, and reliable outcome measures for a condition that varies enormously between individuals. Peptide research for keloids has concentrated in cell culture and animal models because those stages are less costly and faster to run, and most compounds are still working through that phase. The thin clinical trial record reflects where the research lifecycle sits, not a lack of scientific interest in the problem.

Should someone who is keloid-prone avoid BPC-157 entirely?

There is not enough data to give a definitive answer either way. The concern is mechanistically grounded, since BPC-157 promotes angiogenesis and keloids are associated with disordered vascular growth in scar tissue, but no study has confirmed that BPC-157 triggers or worsens keloids in humans. People with a known history of keloid formation typically approach BPC-157 with caution for wound management, which is a reasonable response to genuine uncertainty rather than a confirmed risk.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for keloids in one place.